Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-7819
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer ; volume:18 ; number:1 ; day:8 ; month:7 ; year:2020 ; pages:1-9 ; date:12.2020
World journal of surgical oncology ; 18, Heft 1 (8.7.2020), 1-9, 12.2020
- Urheber
-
Elshenawy, Mahmoud A.
Badran, Ahmed
Aljubran, Ali
Alzahrani, Ahmed
Rauf, M. Shahzad
Eldali, Abdelmoneim
Bazarbashi, Shouki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12957-020-01930-8
- URN
-
urn:nbn:de:101:1-2020090623111165120192
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Elshenawy, Mahmoud A.
- Badran, Ahmed
- Aljubran, Ali
- Alzahrani, Ahmed
- Rauf, M. Shahzad
- Eldali, Abdelmoneim
- Bazarbashi, Shouki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pathological complete response after chemotherapy in initially unresectable distal cholangiocarcinoma
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis
Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Prognosis and predictive factors of conversion surgery for initially unresectable advanced colorectal cancer
Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases
Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Pathological complete response after chemotherapy in initially unresectable distal cholangiocarcinoma
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis
Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Prognosis and predictive factors of conversion surgery for initially unresectable advanced colorectal cancer
Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases
Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Pathological complete response after chemotherapy in initially unresectable distal cholangiocarcinoma
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis
Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Prognosis and predictive factors of conversion surgery for initially unresectable advanced colorectal cancer
Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases
Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab